Risk factors for developing ventilator-associated lower respiratory tract infection in patients with severe COVID-19 : a multinational, multicentre study, prospective, observational study
© 2023. The Author(s)..
Around one-third of patients diagnosed with COVID-19 develop a severe illness that requires admission to the Intensive Care Unit (ICU). In clinical practice, clinicians have learned that patients admitted to the ICU due to severe COVID-19 frequently develop ventilator-associated lower respiratory tract infections (VA-LRTI). This study aims to describe the clinical characteristics, the factors associated with VA-LRTI, and its impact on clinical outcomes in patients with severe COVID-19. This was a multicentre, observational cohort study conducted in ten countries in Latin America and Europe. We included patients with confirmed rtPCR for SARS-CoV-2 requiring ICU admission and endotracheal intubation. Only patients with a microbiological and clinical diagnosis of VA-LRTI were included. Multivariate Logistic regression analyses and Random Forest were conducted to determine the risk factors for VA-LRTI and its clinical impact in patients with severe COVID-19. In our study cohort of 3287 patients, VA-LRTI was diagnosed in 28.8% [948/3287]. The cumulative incidence of ventilator-associated pneumonia (VAP) was 18.6% [610/3287], followed by ventilator-associated tracheobronchitis (VAT) 10.3% [338/3287]. A total of 1252 bacteria species were isolated. The most frequently isolated pathogens were Pseudomonas aeruginosa (21.2% [266/1252]), followed by Klebsiella pneumoniae (19.1% [239/1252]) and Staphylococcus aureus (15.5% [194/1,252]). The factors independently associated with the development of VA-LRTI were prolonged stay under invasive mechanical ventilation, AKI during ICU stay, and the number of comorbidities. Regarding the clinical impact of VA-LRTI, patients with VAP had an increased risk of hospital mortality (OR [95% CI] of 1.81 [1.40-2.34]), while VAT was not associated with increased hospital mortality (OR [95% CI] of 1.34 [0.98-1.83]). VA-LRTI, often with difficult-to-treat bacteria, is frequent in patients admitted to the ICU due to severe COVID-19 and is associated with worse clinical outcomes, including higher mortality. Identifying risk factors for VA-LRTI might allow the early patient diagnosis to improve clinical outcomes.Trial registration: This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 21. Apr., Seite 6553 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 27.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-32265-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355892995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355892995 | ||
| 003 | DE-627 | ||
| 005 | 20231226210257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-32265-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355892995 | ||
| 035 | |a (NLM)37085552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reyes, Luis Felipe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors for developing ventilator-associated lower respiratory tract infection in patients with severe COVID-19 |b a multinational, multicentre study, prospective, observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Around one-third of patients diagnosed with COVID-19 develop a severe illness that requires admission to the Intensive Care Unit (ICU). In clinical practice, clinicians have learned that patients admitted to the ICU due to severe COVID-19 frequently develop ventilator-associated lower respiratory tract infections (VA-LRTI). This study aims to describe the clinical characteristics, the factors associated with VA-LRTI, and its impact on clinical outcomes in patients with severe COVID-19. This was a multicentre, observational cohort study conducted in ten countries in Latin America and Europe. We included patients with confirmed rtPCR for SARS-CoV-2 requiring ICU admission and endotracheal intubation. Only patients with a microbiological and clinical diagnosis of VA-LRTI were included. Multivariate Logistic regression analyses and Random Forest were conducted to determine the risk factors for VA-LRTI and its clinical impact in patients with severe COVID-19. In our study cohort of 3287 patients, VA-LRTI was diagnosed in 28.8% [948/3287]. The cumulative incidence of ventilator-associated pneumonia (VAP) was 18.6% [610/3287], followed by ventilator-associated tracheobronchitis (VAT) 10.3% [338/3287]. A total of 1252 bacteria species were isolated. The most frequently isolated pathogens were Pseudomonas aeruginosa (21.2% [266/1252]), followed by Klebsiella pneumoniae (19.1% [239/1252]) and Staphylococcus aureus (15.5% [194/1,252]). The factors independently associated with the development of VA-LRTI were prolonged stay under invasive mechanical ventilation, AKI during ICU stay, and the number of comorbidities. Regarding the clinical impact of VA-LRTI, patients with VAP had an increased risk of hospital mortality (OR [95% CI] of 1.81 [1.40-2.34]), while VAT was not associated with increased hospital mortality (OR [95% CI] of 1.34 [0.98-1.83]). VA-LRTI, often with difficult-to-treat bacteria, is frequent in patients admitted to the ICU due to severe COVID-19 and is associated with worse clinical outcomes, including higher mortality. Identifying risk factors for VA-LRTI might allow the early patient diagnosis to improve clinical outcomes.Trial registration: This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Rodriguez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fuentes, Yuli V |e verfasserin |4 aut | |
| 700 | 1 | |a Duque, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gallo, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Bastidas, Alirio |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-Mayorga, Cristian C |e verfasserin |4 aut | |
| 700 | 1 | |a Ibáñez-Prada, Elsa D |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez-Valbuena, Paula C |e verfasserin |4 aut | |
| 700 | 1 | |a Ospina-Tascon, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Edwin |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Ana Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Jibaja, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Vera-Alarcon, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Emili |e verfasserin |4 aut | |
| 700 | 1 | |a Bodí, María |e verfasserin |4 aut | |
| 700 | 1 | |a Solé-Violán, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Albaya-Moreno, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Socias, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Figueroa, William |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano-Villanueva, Jose L |e verfasserin |4 aut | |
| 700 | 1 | |a Varón-Vega, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Estella, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Loza-Vazquez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Jorge-García, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar-Hari, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Loeches, Ignacio |e verfasserin |4 aut | |
| 700 | 0 | |a LIVEN-Covid-19 |e verfasserin |4 aut | |
| 700 | 0 | |a SEMICYUC Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Gorordo, Luis Antonio |e investigator |4 oth | |
| 700 | 1 | |a Buitrago, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Poveda, Marcela |e investigator |4 oth | |
| 700 | 1 | |a Saucedo, Lina Maria |e investigator |4 oth | |
| 700 | 1 | |a Estenssoro, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Ortiz, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Nin, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Arango, Alfonso Jose |e investigator |4 oth | |
| 700 | 1 | |a Aguilar, Alvaro |e investigator |4 oth | |
| 700 | 1 | |a Ayala, Andrea Lizeth |e investigator |4 oth | |
| 700 | 1 | |a Bayona, Andrea Viviana |e investigator |4 oth | |
| 700 | 1 | |a Ayala, Andrea Lizeth |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Angelica |e investigator |4 oth | |
| 700 | 1 | |a Aponte, Carol Viviana |e investigator |4 oth | |
| 700 | 1 | |a Forero-Carreño, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Conny Stefanny |e investigator |4 oth | |
| 700 | 1 | |a Estrada, Cristian Augusto |e investigator |4 oth | |
| 700 | 1 | |a Romero, Cristopher |e investigator |4 oth | |
| 700 | 1 | |a Trujillo, Danilo |e investigator |4 oth | |
| 700 | 1 | |a Holguin, Diego |e investigator |4 oth | |
| 700 | 1 | |a Chavez-Villegas, Jesus |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Faure |e investigator |4 oth | |
| 700 | 1 | |a Franco, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Hernan |e investigator |4 oth | |
| 700 | 1 | |a Moncayo, Janett Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Pinedo, Jennifer A |e investigator |4 oth | |
| 700 | 1 | |a Bravo, Jesica Valeria |e investigator |4 oth | |
| 700 | 1 | |a Cruz, Jose David |e investigator |4 oth | |
| 700 | 1 | |a Angel, Jose Miguel |e investigator |4 oth | |
| 700 | 1 | |a Castro-Lara, Jovany |e investigator |4 oth | |
| 700 | 1 | |a Mantilla, Karen Andrea |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Lorena |e investigator |4 oth | |
| 700 | 1 | |a Pabón, Lorena |e investigator |4 oth | |
| 700 | 1 | |a Lopez, Luis Arturo |e investigator |4 oth | |
| 700 | 1 | |a Mamani, Luis Fernando |e investigator |4 oth | |
| 700 | 1 | |a Yupa, Marisa Lucrecia |e investigator |4 oth | |
| 700 | 1 | |a Quevedo, Valeria Catalina |e investigator |4 oth | |
| 700 | 1 | |a Loza, Ana |e investigator |4 oth | |
| 700 | 1 | |a Zapata, Diego Matallana |e investigator |4 oth | |
| 700 | 1 | |a Torres, Isabel Díaz |e investigator |4 oth | |
| 700 | 1 | |a Cuadros, Sonia Ibañez |e investigator |4 oth | |
| 700 | 1 | |a Nuñez, María Recuerda |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Maria Luz Carmona |e investigator |4 oth | |
| 700 | 1 | |a Ramos, Jorge Gómez |e investigator |4 oth | |
| 700 | 1 | |a Casas, Alba Villares |e investigator |4 oth | |
| 700 | 1 | |a Cantón, María Luisa |e investigator |4 oth | |
| 700 | 1 | |a Contreras, José Javier González |e investigator |4 oth | |
| 700 | 1 | |a Chomón, Helena Pérez |e investigator |4 oth | |
| 700 | 1 | |a Chicote, Nerissa Alvarez |e investigator |4 oth | |
| 700 | 1 | |a González, Alberto Sousa |e investigator |4 oth | |
| 700 | 1 | |a De Alba Aparicio, María |e investigator |4 oth | |
| 700 | 1 | |a García, Ruth Jorge |e investigator |4 oth | |
| 700 | 1 | |a Montori, Laura Sánchez |e investigator |4 oth | |
| 700 | 1 | |a García, Sandra Herrero |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Paula Abanses |e investigator |4 oth | |
| 700 | 1 | |a García, Carlos Mayordomo |e investigator |4 oth | |
| 700 | 1 | |a Bonet, Tomás Mallor |e investigator |4 oth | |
| 700 | 1 | |a Bonafonte, Paula Omedas |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Enric Franquesa |e investigator |4 oth | |
| 700 | 1 | |a Vidales, Nestor Bueno |e investigator |4 oth | |
| 700 | 1 | |a Buil, Paula Ocabo |e investigator |4 oth | |
| 700 | 1 | |a Arbeloa, Carlos Serón |e investigator |4 oth | |
| 700 | 1 | |a Sancho, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Ibañez, Pablo Guerrero |e investigator |4 oth | |
| 700 | 1 | |a Gutierrez, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Valdovinos, María Concepción |e investigator |4 oth | |
| 700 | 1 | |a Canto, Raquel |e investigator |4 oth | |
| 700 | 1 | |a García, Ruth Jorge |e investigator |4 oth | |
| 700 | 1 | |a Montori, Laura Sánchez |e investigator |4 oth | |
| 700 | 1 | |a García, Sandra Herrero |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Paula Abanses |e investigator |4 oth | |
| 700 | 1 | |a García, Carlos Mayordomo |e investigator |4 oth | |
| 700 | 1 | |a Bonet, Tomás Mallor |e investigator |4 oth | |
| 700 | 1 | |a Bonafonte, Paula Omedas |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Enric Franquesa |e investigator |4 oth | |
| 700 | 1 | |a Vidales, Nestor Bueno |e investigator |4 oth | |
| 700 | 1 | |a Buil, Paula Ocabo |e investigator |4 oth | |
| 700 | 1 | |a Arbeloa, Carlos Serón |e investigator |4 oth | |
| 700 | 1 | |a Sancho, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Ibañez, Pablo Guerrero |e investigator |4 oth | |
| 700 | 1 | |a Gutierrez, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Valdovinos, María Concepción |e investigator |4 oth | |
| 700 | 1 | |a Canto, Raquel |e investigator |4 oth | |
| 700 | 1 | |a Mariño, Ana Luz Balán |e investigator |4 oth | |
| 700 | 1 | |a Fernández, María José Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Cuadrado, Marta Martín |e investigator |4 oth | |
| 700 | 1 | |a Arias, Belén García |e investigator |4 oth | |
| 700 | 1 | |a Espina, Lorena Forcelledo |e investigator |4 oth | |
| 700 | 1 | |a Soria, Lucía Viña |e investigator |4 oth | |
| 700 | 1 | |a Iglesias, Lorena Martín |e investigator |4 oth | |
| 700 | 1 | |a Amor, Lucía López |e investigator |4 oth | |
| 700 | 1 | |a Rey, Elisabet Fernández |e investigator |4 oth | |
| 700 | 1 | |a Prieto, Emilio García |e investigator |4 oth | |
| 700 | 1 | |a Ruíz, Débora Fernández |e investigator |4 oth | |
| 700 | 1 | |a González, Carla Martínez |e investigator |4 oth | |
| 700 | 1 | |a Socias, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Borges-Sá, Marcio |e investigator |4 oth | |
| 700 | 1 | |a Pérez, María Aranda |e investigator |4 oth | |
| 700 | 1 | |a Socias, Antonia |e investigator |4 oth | |
| 700 | 1 | |a Goytisolo, José Ma Bonell |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 21. Apr., Seite 6553 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:21 |g month:04 |g pages:6553 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-32265-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 21 |c 04 |h 6553 | ||